Intellia Therapeutics (NTLA) - CRISPR-Spezialist überzeugt mit starker Pipeline!
Geschäftstreiber: Intellia Therapeutics (NTLA) hat sich auf die Behandlung von genetischen Krankheiten spezialisiert und setzt dabei vor allem auf die…
26,007$
0,37%
Echtzeit-Aktienkurs Intellia Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Intellia Therapeutics Inc. Aktie
Intellia Therapeutics (NTLA) Upgraded to Buy: Heres What You Should Know
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Heres What You Should Know
The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this…
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this…
Intellia Therapeutics stock hits 52-week high at 21.49 USD By Investing.com
Intellia Therapeutics stock hits 52-week high at 21.49 USD…
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting…
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
…
Intellia Therapeutics: Wells Fargo sieht 173 % Kurspotenzial!
Intellia Therapeutics (NTLA) hat es auf die Liste der Top-10 Kursziele der Analysten geschafft. Der Biotech hat bereits in den…
Citizens JMP reiterates Market Perform rating on Intellia Therapeutics stock By Investing.com
Citizens JMP reiterates Market Perform rating on Intellia Therapeutics stock…
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
…
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Editas Medicine Is Great. Heres Why You Shouldnt Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led…
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
The mean of analysts price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this…
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA
NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and ICON and Encourages Investors to Contact the Firm
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
NEW YORK, March 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To…
Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)
…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the…
ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?
Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
NEW YORK, Feb. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
The mean of analysts price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this…
Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA
Robbins LLP is Investigating Allegations that Intellia Therapeutics, Inc. (NTLA) Misled Investors Regarding the Viability of its Drug Candidate…
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To…
Intellia Therapeutics: Buying The Path To Commercialization
…
Intellia Therapeutics stock falls following strategic reorganization By Investing.com
Intellia Therapeutics stock falls following strategic reorganization…
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by…
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
CRISPR Therapeutics (NASDAQ: CRSP) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential…
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication…
Intellia Therapeutics Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
…
Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung – die Hintergründe
Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr.…
Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung – die Hintergründe
Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr.…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
…
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript
…
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
Theres nothing bearish at all about what it reported recently.…
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? @themotleyfool #stocks $NTLA
Theres nothing bearish at all about what it reported recently.…
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
…
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study By Investing.com
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study…
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street @themotleyfool #stocks $NTLA
Intellia Therapeutics innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.…
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…